BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Biotechgate//Events//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:event-2722@biotechgate.com
DTSTAMP:20261103T222317Z
DTSTART;VALUE=DATE:20261119
DTEND;VALUE=DATE:20261120
SUMMARY:Agile Leaders Forum on Dealmaking & Investment Strategies
DESCRIPTION:A thought leadership workshop for Business &amp\; Research Lead
 ers from life sciences innovation companies and investors\n\nAre you a busi
 ness leader of a Life Science Innovation company or investor?\nAre you inte
 rested in discussing current dealmaking and investment strategies that are 
 working?\nDo want to learn more about other people's experiences\, or share
  your thoughts and queries around investment &amp\; dealmaking?\nAre you lo
 oking to learn from\, and meet with\, your peers and experienced industry p
 rofessionals and seasoned investors?\n\nWhat are the Dealmaking &amp\; Inve
 stment Strategies that are working?\nThe life sciences and biotech sector i
 s currently grappling with a range of investment challenges shaped by regul
 atory pressures\, evolving market dynamics\, and shifting public sentiment.
  As the industry strives to recover from the pandemic&rsquo\;s disruption\,
  deal-making has become more cautious and complex\, reflecting the demand f
 or robust compliance and transparency.\nOne significant challenge is the in
 creased regulatory scrutiny following COVID-19. Investors are now prioritiz
 ing companies with clear pathways to regulatory approval and validated clin
 ical data. This trend influences venture capital flows\, as investors seek 
 to minimize risk by backing firms with established compliance measures. Sma
 ller biotech companies\, in particular\, face hurdles in securing funding\,
  as they often lack the resources to navigate the intricate regulatory land
 scape effectively. Moreover\, public perception regarding drug pricing and 
 access is steering investment decisions. Investors are more inclined to sup
 port companies that align their missions with social responsibility and eth
 ical practices.\nThis societal lens encourages firms to develop narratives 
 that emphasize not only financial viability but also positive community imp
 act\, a factor that is increasingly crucial in attracting committed investo
 rs. To address these challenges\, strategic partnerships are emerging as a 
 vital solution. Collaborations between small biotech startups and larger ph
 armaceutical firms can enhance credibility and access to resources\, provid
 ing a safety net for navigating regulatory complexities.\nAdditionally\, th
 e use of non-dilutive funding&mdash\;such as grants and government contract
 s&mdash\;has gained traction\, allowing companies to focus on long-term inn
 ovations without immediate financial pressures.In this evolving landscape\,
  investment strategies that embrace transparency\, collaboration\, and ethi
 cal considerations will be pivotal. As the life sciences sector adapts\, in
 novative approaches will unlock new opportunities for growth\, ensuring a s
 ustainable path forward for the future of healthcare.\nGreen-Shoots? We wil
 l explore what is happening in Europe and the US with experts that know the
  activity in the financial marketplace. We will have Bill Hicks with us fro
 m Mintz in Boston\, US along with James Fry from Mills &amp\; Reeve who has
  his finger on the pulse regarding the UK and EU markets\, along with other
  experts.
LOCATION:London\, United Kingdom
URL:https://www.eventbrite.co.uk/e/agile-leaders-forum-on-dealmaking-invest
 ment-strategies-that-work-tickets-2000005522356
END:VEVENT
END:VCALENDAR